Want to create an interactive transcript for this episode?
Podcast: BioCentury This Week
Episode: Ep. 212 - 2024 Buyside View & Arnold Ventures' Impact
Description: Biotech investors are looking to catalysts that can create, or dramatically expand, commercial markets as they look ahead to a long-awaited recovery for industry. On the latest BioCentury This Week podcast, BioCentury’s editors assess the milestones on buysiders’ radar for 2024, including in areas such as obesity, pain and metabolic-associated steatohepatitis (MASH). They also discuss the influence of biopharma critic Arnold Ventures, a philanthropy that has reshaped the drug pricing public policy landscape; lung cancer data for Gilead's Trodelvy; and the week's expected biotech IPOs. Music for The East-West Biopharma Summit: Singapore teaser:Composed by: Moa Micha...